Blum Brice, Wormack Leah, Holtel Mason, Penwell Alexandria, Lari Shyyon, Walker Brittany, Nathaniel Thomas I
University of South Carolina, School of Medicine-Greenville, Greenville, SC, 29605, USA.
BMC Womens Health. 2019 Jan 16;19(1):11. doi: 10.1186/s12905-018-0698-6.
When untreated, dyslipidemia is a higher risk factor for stroke and stroke-related mortality in men than in women. However, when dyslipidemia is treated the risk reduction is the same, but men benefited from mortality reduction more than women. Whether there is a gender difference in exclusion criteria for the use of recombinant tissue plasminogen activator (rtPA) or thrombolysis therapy in an acute ischemic stroke subpopulation with dyslipidemia is yet to be investigated.
In a dyslipidemic stroke population obtained from a stroke registry, gender differences in exclusion risk factors were determined using clinical and demographic variables. Univariate analysis compared the recombinant tissue plasminogen activator (rtPA) group and the no rtPA group. Multiple regression analysis was used to determine demographic and clinical factors associated with inclusion and exclusion for rtPA in the total dyslipidemic stroke population and the subsets of the male and female population. The regression model was tested using the Hosmer-Lemeshow test, for the overall correct classification percentage. Significant interactions and multicollinearity between independent variables were examined using variance inflation factors.
A total of 769 patients presented with acute ischemic stroke with incidence dyslipidemia; 325 received rtPA while 444 were excluded from rtPA. Of those excluded from rtPA, 54.30% were female and 45.72% were male. In an adjusted analysis, female patients with increased age (OR = 1.024, 95% CI, 1.001-1.047, P < 0.05), with a history of carotid artery stenosis (OR = 7.063, 95% CI, 1.506-33.134, P < 0.05), and previous stroke (OR = 1.978, 95% CI, 1.136-3.442, P < 0.05) were more likely to be excluded from rtPA. Male patients with atrial fibrillation (OR = 2.053, 95% CI, 1.059-3.978, P = 0.033), carotid artery stenosis (OR = 2.400, 95% CI, 1.062-5.424, P = 0.035), and previous stroke (OR = 1.785, 95% CI, 1.063-2.998, P = 0.028) were more likely to be excluded from rtPA.
Although there are some similarities in the clinical risk factors for exclusion in both male and female stroke patients with incidence of dyslipidemia, there are differences as well. Elderly female stroke patients with incidence of dyslipidemia are more likely to be excluded from rtPA, even after adjustment for the effect of confounding variables. Further research should focus on how identified clinical risk factors can be targeted and managed to improve the use of rtPA in elderly female acute ischemic stroke population with incidence of dyslipidemia.
未经治疗时,血脂异常在男性中是比女性更高的中风及中风相关死亡率的风险因素。然而,当血脂异常得到治疗时,风险降低程度相同,但男性在死亡率降低方面比女性受益更多。在患有血脂异常的急性缺血性中风亚组中,使用重组组织型纤溶酶原激活剂(rtPA)或溶栓治疗的排除标准是否存在性别差异尚待研究。
在从一个中风登记处获得的血脂异常中风人群中,使用临床和人口统计学变量确定排除风险因素中的性别差异。单因素分析比较了重组组织型纤溶酶原激活剂(rtPA)组和非rtPA组。多因素回归分析用于确定在整个血脂异常中风人群以及男性和女性亚组中与rtPA纳入和排除相关的人口统计学和临床因素。使用Hosmer-Lemeshow检验对回归模型进行检验,以得出总体正确分类百分比。使用方差膨胀因子检查自变量之间的显著交互作用和多重共线性。
共有769例患有急性缺血性中风且伴有血脂异常的患者;325例接受了rtPA治疗,而444例被排除在rtPA治疗之外。在被排除在rtPA治疗之外的患者中,54.30%为女性,45.72%为男性。在调整分析中,年龄增加的女性患者(OR = 1.024,95% CI,1.001 - 1.047,P < 0.05)、有颈动脉狭窄病史的女性患者(OR = 7.063,95% CI,1.506 - 33.134,P < 0.05)以及有既往中风史的女性患者(OR = 1.978,95% CI,1.136 - 3.44)更有可能被排除在rtPA治疗之外。有房颤的男性患者(OR = 2.053,95% CI,1.059 - 3.978,P = 0.033)颈动脉狭窄(OR = 2.400,95% CI,1.062 - 5.424,P = 0.035)以及有既往中风史的男性患者(OR = 1.785,95% CI,1.063 - 2.998)更有可能被排除在rtPA治疗之外。
尽管在患有血脂异常的男性和女性中风患者中,排除的临床风险因素存在一些相似之处,但也存在差异。患有血脂异常的老年女性中风患者即使在调整混杂变量的影响后,仍更有可能被排除在rtPA治疗之外。进一步的研究应侧重于如何针对已确定的临床风险因素进行靶向处理和管理,以改善rtPA在患有血脂异常的老年女性急性缺血性中风人群中的使用情况。